• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Cannabis Market
Cannabis News
Cannabis Stocks
  • Cannabis Market
  • Cannabis News
  • Cannabis Stocks

Zenabis Delays Facility Expansion to Protect Cash Flow

Written by Bryan Mc Govern
|
Oct. 21, 2019 04:25PM PST

Shares of Zenabis Global dropped on Monday after the company confirmed it is delaying a segment of its facility expansion in Langley, British Columbia.

A Canadian cannabis producer has adjusted its construction plans for a facility expansion in British Columbia, Canada, in an attempt to prevent disruption to its cash flow.

In an update to investors issued on Monday (October 21), Zenabis Global (TSX:ZENA) confirmed the adjusted timeline for the facility. The new plan will delay the site in reaching full capacity.

According to Andrew Grieve, CEO of Zenabis, the facility will still achieve production of 96,400 kilograms by the end of 2019.

Zenabis will split its remaining Zenabis Langley expansion into two phases: Zenabis Langley — Part 2B and Zenabis Langley — Part 2C.

“While the timeline revision for Zenabis Langley will delay achieving full design capacity at the facility, we expect to have 96,400 kg of capacity licensed and operational by the end of 2019 with approval of the Zenabis Langley – Part 2A amendment,” Grieve said.

Zenabis filed an amendment for the 2A phase of its expansion in September and anticipates it will obtain Health Canada approval this year.

The firm plans to submit its license amendment to the regulator for the 2B section in November, while 2C will have to wait until early 2020.

Zenabis indicated that this decision was made due to market conditions at the moment and as way to lower ramp-up risk.

The marijuana producer has lofty expectations for its facility operations and production in Langley.

“By early in the first quarter of 2020, we expect to have 111,200 kilograms of capacity licensed and operational with the approval of the Zenabis Langley — Part 2B amendment,” Grieve said.

The market did not take kindly to the delay in Monday’s trading session. Shares of Zenabis opened at C$0.68 and then quickly fell by 4.41 percent to C$0.65 as of 10:35 a.m. EDT following the announcement.

On analyst data aggregator TipRanks, Zenabis currently holds a “moderate buy” rating based on two recent reviews of the stock.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

zenabis global andrew grieve british columbia canada tsx:zena
The Conversation (0)

Go Deeper

AI Powered

Cannabis Update: Q1 2018 in Review

Next Green Wave Unveils Flagship CBD Store In San Diego, California

Next Green Wave Unveils Flagship CBD Store In San Diego, California

Latest News

More News

Outlook Reports world

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
  • Energy
    • Uranium
    • Oil and Gas
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Industrial Metals
  • Agriculture
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Gaming
    • Cleantech
    • Emerging Tech
Life Science
    • Biotech
    • Cannabis
    • Psychedelics
    • Pharmaceuticals

Featured Cannabis Investing News Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES